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ADENOSINE is known to cause vasodilation and to inhibit neutrophil activation, platelet aggregation, 
endothelin production, and superoxide production in the 
myocardium after ischemia and reperfusion.! To exploit 
these biological effects of adenosine to prevent tissue injury 
from ischemia and reperfusion, exogenous adenosine sup-
plementation and endogenous adenosine supplement have 
been used experimentally. The aim of this study is to 
determine whether endogenous adenosine supplementa-
tion by inhibition of nucleoside transport (R 75231) or 
adenosine deaminase (EHNA) can attenuate ischemial 
reperfusion injury to the canine liver. 
MATERIALS AND METHODS 
Two-hour complete hepatic ischemia was induced in adult female 
beagle dogs by clamping the vena cava (above and below the liver), 
and the portal triad. Splanchnic and inferior systemic venous beds 
were decompressed using veno-venous bypass. R 75231 at a dose of 
0.05 mg/kg (n = 5. Janssen Research Foundation. Beerse, Belgium) 
and EHNA at a dose of 10 mg/kg (n = 5, Sigma, St Louis, Mo) were 
given as a continuous intravenous infusion (via a peripheral vein) 
over 30 minutes. just before hepatic ischemia. Control animals (n = 
10) received no treatment. Animal survival, hepatic tissue blood 
flow, liver function. adenine nucleotides, purine catabolites and 
histopathology were analyzed. Results are presented as the mean :+: 
the standard error of the mean. Statistical analysis of the results 
was performed using the Log Rank test (for survival). and the 
Mann-Whitney U test (all others). A p value less than .05 was 
considered significant. 
RESULTS 
Two-week animal survival in the Control group (30%) was 
significantly worse than the R75321 group 2 (100%), but 
not different from the EHNA group (60%). Peak AST and 
ALT levels in the Control and EHNA groups were signifi-
cantly higher than AST and AL T levels in the R 75231 group 
(Fig I a). During and after ischemia. adenosine levels and 
adenine nucleotide levels in the EHNA group were signif-
icantly higher than the levels in the Control and R75231 
groups. However, hypoxanthine levels in the R75231 group 
were significantly lower than the Control and EHNA 
groups. The recovery of energy charge. and adenine nucleo-
tides. particularly ATP. after reperfusion was significantly 
hetter in the R75231 and EHNA groups Ulan the Control 
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group. Tissue blood flow after reperfusion was significantly 
better in the R75231 and EHNA groups than the Controls 
(Fig Ib). Histological analysis of post-ischemic liver tissue 
revealed that hepatocyte necrosis was similar among the 
EHNA and Control groups, but hepatocyte necrosis in the 
R75231 group was significantly lower than the other groups. 
DISCUSSION 
The effect of augmentation of endogenous adenosine was 
different based upon the inhibitor used. While inhibition of 
adenosine deaminase by EHNA significantly augmented 
adenine nucIeotides and improved post-reperfusion blood 
flow, it did not significantly improve survival, liver function, 
nor liver histology. However. the augmentation of endoge-
nous adenosine by the nucleoside transport inhibitor signif-
icantly improved survival, hepatic tissue blood flow, liver 
function, and liver histology. 
There are several possible explanations for the difference 
in effectiveness among EHNA and R75231. First the inabil-
ity of EHNA to protect the liver may be related to 
inhibition of other reactions. such as inhibition of dynein 
ATPase activity and actin dependent cellular processes.3 
Second, the high adenosine levels caused by EHNA may 
induce systemic adverse events. including hypertension, 
renal vasoconstriction, and reduction of hepatic blood flow. 
Third, the high adenosine level induced by EHNA may 
stimulate purine catabolism and the production of super-
oxides through the xanthine oxidase system:' A final expla-
nation for the difference between R75231 and EHNA may 
be related to the mechanism of action of R75231. R75231 
prevents the transport of adenosine from the hepatocyte 
and endothelial cells. It docs not. however. prevent the 
transport of AMP from these cells. When AMP is trans-
ported into the interstitial space it is broken down to 
adenosine. The high adenosine levels in the interstitial 
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Fig 1. Liver function and hepatic tissue blood flow. 
space may protect the hepatocyte and endothelial cells from 
ischemia and reperfusion injury. 
Higher adenine nucleotide levels and adenosine levels in 
the ischemic liver was not associated with better post-
ischemic liver function nor animal survival. Augmentation 
of endogenous adenosine by the nucleotide transport inhib-
itor, R75231, attenuated ischemia and reperfusion injury, 
while EHNA did not. 
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